Trial results

Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

NCT07829198 on ClinicalTrials.gov · last registry update 2026-09-18

A small phase 3 — 70 participants, against a typical 424. Due to report December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percentage Change in Body Weight from Baseline to Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

tirzepatide

Mounjaro, Zepbound

Sponsor

Universidade do Porto

Sponsor type

Other

Enrollment

70

Started

2027-01

Primary completion

2028-12 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percentage Change in Body Weight from Baseline to Week 52

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.